



Phylogeography and resistome of pneumococcal meningitis in 
West Africa before and after vaccine introduction
Madikay Senghore1,2, Peggy- Estelle Tientcheu1, Archibald Kwame Worwui1, Sheikh Jarju1, Catherine Okoi1, Sambou M. 
S. Suso1, Ebenezer Foster- Nyarko1, Chinelo Ebruke1, Mohamadou Sonko3, Mamdou Hama Kourna4, Joseph Agossou5,6, 
Enyonam Tsolenyanu7, Lorna Awo Renner8, Daniel Ansong9, Bakary Sanneh10, Catherine Boni Cisse11, Angeline Boula12, 
Berthe Miwanda13, Stephanie W. Lo14, Rebecca A. Gladstone14, Stephanie Schwartz15, Paulina Hawkins15,16, 
Lesley McGee15, Keith P. Klugman16, Robert F. Breiman16,17, Stephen D. Bentley14, Jason M. Mwenda18, Brenda 
Anna Kwambana- Adams1,19† and Martin Antonio1,*,†
RESEARCH ARTICLE
Senghore et al., Microbial Genomics 2021;7:000506
DOI 10.1099/mgen.0.000506
000506 © 2021 The Authors
This is an open- access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between 
the Microbiology Society and the corresponding author’s institution.
Abstract
Despite contributing to the large disease burden in West Africa, little is known about the genomic epidemiology of Strep-
tococcus pneumoniae which cause meningitis among children under 5 years old in the region. We analysed whole- genome 
sequencing data from 185 S. pneumoniae isolates recovered from suspected paediatric meningitis cases as part of the 
World Health Organization (WHO) invasive bacterial diseases surveillance from 2010 to 2016. The phylogeny was recon-
structed, accessory genome similarity was computed and antimicrobial- resistance patterns were inferred from the genome 
data and compared to phenotypic resistance from disc diffusion. We studied the changes in the distribution of serotypes 
pre- and post- pneumococcal conjugate vaccine (PCV) introduction in the Central and Western sub- regions separately. The 
overall distribution of non- vaccine, PCV7 (4, 6B, 9V, 14, 18C, 19F and 23F) and additional PCV13 serotypes (1, 3, 5, 6A, 19A 
and 7F) did not change significantly before and after PCV introduction in the Central region (Fisher's test P value 0.27) 
despite an increase in the proportion of non- vaccine serotypes to 40 % (n=6) in the post- PCV introduction period compared 
to 21.9 % (n=14). In the Western sub- region, PCV13 serotypes were more dominant among isolates from The Gambia fol-
lowing the introduction of PCV7, 81 % (n=17), compared to the pre- PCV period in neighbouring Senegal, 51 % (n=27). The 
phylogeny illustrated the diversity of strains associated with paediatric meningitis in West Africa and highlighted the exist-
ence of phylogeographical clustering, with isolates from the same sub- region clustering and sharing similar accessory 
genome content. Antibiotic- resistance genotypes known to confer resistance to penicillin, chloramphenicol, co- trimoxazole 
and tetracycline were detected across all sub- regions. However, there was no discernible trend linking the presence of 
resistance genotypes with the vaccine introduction period or whether the strain was a vaccine or non- vaccine serotype. 
Resistance genotypes appeared to be conserved within selected sub- clades of the phylogenetic tree, suggesting clonal 
inheritance. Our data underscore the need for continued surveillance on the emergence of non- vaccine serotypes as well 
as chloramphenicol and penicillin resistance, as these antibiotics are likely still being used for empirical treatment in low- 
resource settings. This article contains data hosted by Microreact.
DATA SUMMARY
The sequencing reads for the genomes analysed have been 
deposited in the European Nucleotide Archive and the acces-
sion numbers for each isolate are listed in Table S1 (available 
with the online version of this article). A phylogenetic tree 
and associated metadata are available on Microreact: https:// 
microreact. org/ project/ HJcM_ 9lxf.
INTRODUCTION
Streptococcus pneumoniae (the pneumococcus) is one 
of the top three causes of acute bacterial meningitis, the 
most severe form of meningitis [1]. Despite the avail-
ability of effective vaccines, acute bacterial meningitis due 
to the pneumococcus continues to be a major cause of 
morbidity and mortality in sub- Saharan Africa, especially 
among children under 5 years old [2]. The 10- or 13- valent 
pneumococcal conjugate vaccine (PCV10 and PCV13 
respectively), which target the most prevalent serotypes in 
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sub- Saharan Africa. PCVs have been effective at reducing 
invasive disease caused by vaccine serotypes in high- income 
countries and low- resource settings [3–7].
Whole- genome sequencing has emerged as a useful 
technique for typing bacteria because it provides high- 
resolution inter- isolate comparisons, which can provide 
insights into pneumococcal transmission and evolution 
[8, 9]. For example, in 2016, 3 years post- PCV13 introduc-
tion, we identified a novel clade of sequence type (ST) 
303 serotype 1 pneumococcus, which caused a meningitis 
outbreak in Ghana [10]. Access to genome sequencing and 
a well- defined global phylogeny of serotype 1 strains [11] 
allowed us to place the outbreak isolates in a global context. 
Unfortunately, in most West and Central African settings 
there remains a paucity of genomic data for pneumococcal 
serotypes associated with invasive disease.
An added advantage of genome sequencing is that it allows 
the prediction of resistance to commonly prescribed anti-
biotics [12]. For example, macrolide, chloramphenicol and 
tetracycline resistance can be predicted by the presence of 
the horizontally acquired ermB and ormef, cat and tetM 
genes, respectively [12–15]. Similarly, rifampicin, peni-
cillin and co- trimoxazole resistance can be inferred based 
on known mutations in rpoB, penicillin binding protein 
genes pbp1A, pbp2B and pbp2X, and folA/folP genes, respec-
tively [10, 12–16]. Through genomics, we can identify the 
emergence and spread of multidrug- resistant clones that 
could pose a serious public- health threat, especially in high 
disease burden settings.
We present genomic analysis of 185 pneumococcal isolates 
from children with confirmed meningitis in West Africa 
between 2010 and 2016. The collection of these isolates was 
facilitated through the World Health Organization (WHO) 
Invasive Bacterial Vaccine- Preventable Disease (IB- VPD) 
sentinel surveillance network. Our analysis probes the 
effect of PCV introduction on the genomic epidemiology 
of pneumococci causing paediatric meningitis. We also 
studied the potential effects of PCV introduction on the 
distribution of antibiotic- resistance genes. These data 
provide the first baseline data on the genomic epidemiology 
of pneumococcal paediatric meningitis in West Africa pre- 
and post- PCV introduction.
METHODS
Study design
The WHO IB- VPD surveillance is supported by the WHO 
Collaborating Centre (WHO CC) for New Vaccines Surveil-
lance hosted by the Medical Research Council Unit The 
Gambia at the London School of Hygiene and Tropical 
Medicine (MRCG). Within this framework, vaccine 
preventable meningitis surveillance has been on- going 
in 11 countries across 17 sentinel sites since 2010. As 
part of the surveillance, bacterial isolates recovered from 
suspected paediatric meningitis cases were sent to the 
Impact Statement
Streptococcus pneumoniaecauses severe diseases 
including meningitis and pneumonia which are leading 
causes of morbidity and mortality in sub- Saharan Africa, 
particularly among children. Resource constraints make it 
difficult to carry out paediatric infectious disease surveil-
lance in this setting. We compiled a genomic dataset of S. 
pneumoniae strains associated with paediatric bacterial 
meningitis in West and Central Africa, collected through 
sentinel surveillance. This unique dataset has allowed us 
to study the genetic determinants of antimicrobial resist-
ance in the pre- and post- PCV introduction periods. We 
also show novel insights into the phylogenetic landscape 
of S. pneumoniae associated with paediatric meningitis 
and highlight patterns consistent with the localization of 
some sublineages by geographical sub- region.
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WHO CC hosted at the MRCG for confirmation, sero-
typing, antibiotic- susceptibility testing and whole- genome 
sequencing in collaboration with the Global Pneumococcal 
Sequencing project (https://www. pneumogen. net/ gps/).
Study population
The study participants were aged between 6 days and 59 
months old, the mean age was 20.8 months and the median 
age was 14 months (age was recorded for 129 patients). This 
dataset also included two older children aged 8 and 16 years 
old. Patients admitted with suspected meningitis at paediatric 
teaching and referral hospitals were enrolled into the surveil-
lance. Isolates for whole- genome sequencing were received 
from sentinel sites in The Gambia, Senegal, Ivory Coast, 
Ghana, Togo, Benin, Niger, Cameroon and the Democratic 
Republic of Congo (Table 1).
Bacteriology
Lumbar puncture was performed to collect cerebrospinal 
fluid (CSF) specimens w. For some patients, specimens were 
also collected from other clinical sites, including blood, lung/
pleural aspirate and pus. Our dataset includes isolates from 
CSF (151, 81.6 %), blood (21, 11.4 %), lung/pleural aspirate (9, 
4.9 %), pus (1, 0.5 %) and 3 (1.6 %) from an unknown source. 
The pneumococcal isolates were cultured using standard tech-
niques and sent to the WHO Regional Reference Laboratory 
(RRL) for further analysis.
Clinical specimens were streaked onto Columbia agar with 
5 % defibrinated sheep blood and incubated overnight in 5 % 
CO2 at 37 °C. Suspected colonies of the pneumococcus were 
confirmed by sensitivity to optochin (Oxoid) and stored in 
16 % (v/v) glycerol broth at −70 °C for shipment to the WHO 
RRL. Confirmation of species and characterization of sero-
types were done by PCR and latex agglutination, as described 
elsewhere [16]. Antimicrobial susceptibility to cefotaxime, 
chloramphenicol, meropenem, vancomycin, co- trimoxazole, 
rifampicin, tetracycline, oxacillin (for penicillin) and eryth-
romycin was performed by disc diffusion, and interpreted 
according to the Clinical and Laboratory Standards Institute 
(CLSI) guidelines. Confirmatory Etest was done for cefo-
taxime and ceftriaxone by colleagues at the US Centers for 
Disease Control and Prevention (CDC). All the disc diffusion 
assays were performed at the WHO RRL. Minimum inhibi-
tory concentrations (MICs) could not be assessed due to the 
inhibitory cost of the kits. The WHO RRL participates in 
external quality assurance (EQA) programmes organized by 
the United Kingdom National External Quality Assessment 
Service (UK NEQAS), the National Institute for Communi-
cable Diseases (NICD), South Africa, and the United States 
Centers for Disease Control and Prevention (US CDC).
Whole-genome sequencing
Genomic DNA was extracted and purified from fresh over-
night cultures of the stored pneumococcal isolates using a 
modified Qiagen extraction protocol as previously described 
[10]. Paired- end sequencing on the Illumina HiSeq platform 
was performed at the Wellcome Sanger Institute, Cambridge, 
UK [17].
Genomic analysis
The in silico serotype and the multilocus sequence type 
(MLST) were determined from the genomes using SeroBA 
[18] and a local alignment of de novo contigs against MLST 
alleles in pubMLST [19], respectively. Sequencing reads were 
mapped to the pneumococcal strain ATCC 700669 reference 
genome (accession no. FM211187) using bwa (version 0.7.17) 
with default parameters [20], the bam files were sorted and 
duplicates were marked using Picard. The mpileup command 
in SAMtools (version 1.2.1) was used to call bases at all sites 
with at least five reads mapped, and output the calls in the 
variant call format (VCF) [21]. A consensus sequence was 
generated and SNPs were called where at least 75 % of reads 
Table 1. Counts of study isolates from each country by vaccine era
Sub- region Country PCV introduction* Pre- PCV [n (%)] Post- PCV [n (%)] Unknown [n (%)] Total
Eastern Cameroon 2011 2 (6.9) 27 (93.1) 0 (0) 29
DR Congo 2011 0 (0) 0 (0) 1 (100) 1
Central Ghana 2012 17 (65.4) 9 (34.6) 0 (0) 26
Benin 2011 3 (60) 2 (40) 0 (0) 5
Ivory Coast 2014 2 (100) 0(0) (0) 2
Niger 2014 23 (92) (0) 2 (8) 25
Togo 2014 19 (82.6) 4 (17.4) 0 (0) 23
Western Senegal 2013 53 (96.4) 2 (3.6) 0 (0) 55
The Gambia 2009 0 (0) 19 (100) 0 (0) 19
Total   – – 119 (64.3) 63 (34.1) 3 (1.6) 185
*Post- PCV period commences the year after the introduction of a PCV vaccine of any valency.
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mapped to the alternative allele. The consensus sequences 
from all genomes were amalgamated into a multiple sequence 
alignment fasta file and variable sites were extracted using 
the SNP- sites program (version 2.5.1) [22]. The maximum- 
likelihood phylogeny was reconstructed from 99 474 variable 
sites in the core genome using RAxML (version 8.2.8) with 
a general time reversible model and 100 bootstrap replicates 
[23]. The phylogenetic tree and associated metadata are 
publicly available on Microreact: https:// microreact. org/ 
project/ HJcM_ 9lxf.
De novo assemblies were generated from sequencing using 
The Sanger Institute assembly pipeline that is described else-
where [24]. Assemblies were annotated using Prokka (version 
1.14.5) [25] and the pan genome was inferred using Roary 
(version 3.12) [26]. Genomes were clustered based on the 
presence and absence of accessory genes using panini [27] 
and visualized in a scatter plot using Microreact. panini uses 
a Student's t- distributed stochastic neighbour embedding 
machine learning algorithm to compute similarities in the 
accessory genome. Antimicrobial resistance was predicted 
based on the presence of known genotypes at loci that are 
associated with antibiotic resistance (rpoB, pbp1A, pbp2B, 
pbp2B and folA/folP genes) using an antibiotic- resistance 
calling pipeline designed for S. pneumoniae [12, 28–31]. The 
ermB/mefA, cat and tetM genes were linked to erythromycin, 
chloramphenicol and tetracycline resistance, respectively. 
Genotypic variants of pbp and folA/folP genes known to confer 
resistance were attributed to penicillin and co- trimoxazole 
resistance, respectively.
Statistical analysis
Data were compiled in Excel and uploaded onto RStudio 
(version 1.2.5033) for statistical analysis. The analyses were 
carried out separately on genomes from the Western and 
Central sub- regions. Paired t- test, chi- square (χ2) test and 
Fisher’s exact test were used to analyse the differences in 
the distribution of vaccine and non- vaccine serotypes in the 
pre- and post- PCV introduction periods. There were only two 
isolates from the pre- PCV period in the Eastern sub- region, 
so no comparisons could be made.
RESULTS
We analysed 185 genomes of pneumococci isolated from 
paediatric meningitis patients across West Africa and parts of 
Central Africa. The isolates were clustered based on country 
into three sub- regions: isolates from Gambia and Senegal 
were clustered as the Western sub- region; Ghana, Togo, Ivory 
Coast, Benin and Niger were clustered as the Central West 
sub- region; and Cameroon and the Democratic Republic 
of Congo represented the Eastern sub- region. We defined 
the pre- PCV period as the time period preceding the first 
introduction of the PCV (any valency) in a given country and 
post- PCV as the time post- introduction of PCV. A third of the 
isolates were recovered from cases that occurred post- PCV 
introduction and two thirds were pre- PCV (Table 1).
Serotype distribution across sub-regions
We classified our strains into serotypes and MLSTs based 
on the whole genome, and visualized their distribution in 
the three sub- regions as a means of studying sub- regional 
diversity. There were 32 serotypes identified among the 
cases, which included 76 unique Sequence Types (STs). Most 
isolates belonged to serotypes 1 (47, 25.4 %), 14 (18, 9.7 %), 5 
(16, 8.6 %) and 23F (14, 7.6 %). Other commonly identified 
serotypes included 19F (10, 5.4 %), 6A (10, 5.4 %), 12F (9, 
4.9 %), 6B (9, 4.9 %) and 15B/15C (6, 3.2 %). Serotype 1 was 
dominant in the West and Central sub- regions, but it was not 
detected in the Eastern sub- region (Fig. 1a, b). Most serotypes 
were uncommon (20, 62.5 %) and were only detected in one 
or two patients (Fig. 1a).
In the Central sub- region, isolates were sequenced from 
64 and 15 patients in the pre- and post- PCV introduction 
periods, respectively. The overall distribution of non- 
vaccine serotypes, PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F 
and 23F) and additional PCV13 serotypes (1, 3, 5, 6A, 19A 
and 7F) did not change significantly before and after PCV 
introduction in the Central region: the proportion of non- 
vaccine serotypes in the post- PCV period was 40 % (n=6) 
compared to the pre- PCV period, 21.9 % (n=14) (Fisher test 
P value 0.27) (Fig. 1c). The proportion of isolates with the 
non- vaccine serotypes 24, 12F, 35B and 23B increased by 
13.3, 8.7, 6.3 and 5.1 %, respectively, in the post- PCV period 
(Fig. 1d, Table S2). In the Western sub- region, all pre- PCV 
isolates were from Senegal (n=53), while 90 % (n=19) of the 
post- PCV introduction isolates were from The Gambia after 
the introduction of PCV7, which precluded a comparison 
based on the PCV era.
Phylogenetic analysis and sub-regional clustering
The phylogenetic tree and a scatter plot depicting simi-
larity of accessory genomes content were annotated with 
sub- region and serotype in order to visualize potential 
clustering of strains from the same sub- region. Phylogeo-
graphical clustering was observed within serotypes, with 
isolates from the same sub- region clustering and sharing 
similar accessory genome content (Fig. 2a). In West Africa, 
sub- regional clustering was observed within the serotype 
1 clade: ST3081 was found only in the Western sub- region, 
while ST303 was the predominant genotype in the Central 
sub- region. Serotype 6A isolates formed two divergent 
clades with markedly different accessory genome content. 
The ST3324 subclade was prevalent in the Western sub- 
region and a ST5547 subclade was prevalent in the Central 
sub- region.
Serotype 5 was not found in the Central sub- region, but in 
the Western sub- region it was the second most common 
serotype. Three unique STs were present in the Western 
sub- region, but in the Eastern sub- region only ST289 
was reported. Serotypes 5, 12F, 14 and 19F had a highly 
conserved serotype specific accessory genome and did not 
vary with ST or sub- region of origin (Fig. 2b).
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Resistance genotypes in the context of sub-region, 
PCV introduction period and phylogeny
Our data confirm the presence of antibiotic- resistance 
genotypes known to confer resistance to penicillin (n=38, 
20.5 %), chloramphenicol (n=18, 9.7 %), co- trimoxazole 
(n=101, 54.6 %), erythromycin (n=3, 1.6 %) and tetracycline 
(n=111, 60 %). There did not appear to be a significant corre-
lation between the presence of antibiotic resistance and 
sub- region (Fig. 3). Likewise, there was no significant trend 
linking the presence of resistance genotypes to the vaccine 
introduction period or whether the strain was a vaccine 
or non- vaccine serotype (Fig.  3). The genotypic predic-
tors of resistance among the isolates were examined in the 
context of the phylogeny. Resistance genotypes appeared to 
be conserved within selected sub- clades of the phylogenetic 
tree (Fig. 4). Within serotype 1, isolates harbouring both 
tetM and folA/ folP resistance genotypes were common in 
the ST303/ST217 sub- clade (n=8, 42 %) but absent in the 
ST3081 (n=0), and only four isolates in the ST618 sub- clade 
(20 %) bore the tetM resistance gene (Fig. 4). Prediction 
of antimicrobial susceptibility from the genome has been 
found to have good correlation with phenotypic data [12]. 
However, we noted 23 (12.4 %) chloramphenicol- resistant 
cases but the cat gene was only detected in 13 (56.3 %) cases. 
Similarly, among 33 penicillin- resistant cases, 24 (72.7 %) 
had a pbp genotype known to confer resistance. Unfortu-
nately, we were unable to perform phenotypic antimicrobial 
susceptbility retesting to confirm the results.
DISCUSSION
Our dataset offers important insights into the genomic epide-
miology of S. pneumoniae associated with meningitis in West 
and Central Africa, a high- burden region with a paucity of 
genomic and epidemiological data. Phylogeographical clus-
ters of isolates causing meningitis in the same geographical 
sub- region shared similar accessory genome content. The 
pneumococcus has an open pan genome that can readily 
acquire accessory genes from microbes within its ecological 
niche, making it highly adaptable to its environment [32, 33]. 
The accessory genome content plays a major role in deter-
mining the fitness of pneumococcal lineages and re- shaping 
the perturbed bacterial population structure following major 
clinical interventions like vaccination [34, 35]. Further work 
needs to be done to determine whether children in some parts 
of West and Central Africa are at a greater risk of developing 
Fig. 1. Distribution of the major S. pneumoniae serotypes and genotypes among isolates from suspected paediatric meningitis cases 
pre- and post- PCV introduction in West and Central Africa grouped by sub- region. (a) A map of West Africa including Cameroon with pie 
charts showing the distribution of the main serotypes. (b) A map with pie charts showing the distribution of the main STs. (c) A stacked 
column plot showing the proportion of isolates bearing non- vaccine serotypes, PCV7 serotypes and additional PCV13 serotypes before 
and after the introduction of PCV. (d) A bar graph showing the change in prevalence of the most common serotypes before and after PCV 
introduction in the Western and Central sub- regions.
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Fig. 2. Phylogeny of S. pneumoniae genotypes causing paediatric meningitis in West and Central Africa, and a scatter plot showing 
accessory genome similarity. (a) A phylogenetic tree annotated with branches coloured by serotype, with metadata rings to show sub- 
region of origin, vaccine era and vaccine type with ST displayed as text on the outer ring. (b) A panini accessory genome scatter plot 
where each point, representing one isolate, is coloured by serotype, and distances between points are proportional to accessory genome 
similarity. The panini plot is by major serotypes (in bold) and the STs that demonstrate geographical clustering.
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meningitis due to the presence of virulent pneumococcal 
lineages.
Although our dataset was not powered to study the impact of 
PCV on the epidemiology of pneumococcal bacterial menin-
gitis among children, we gleaned some observations on the 
distribution of serotypes before and after the introduction 
of PCV. Serotype 1 remained a leading cause of paediatric 
pneumococcal meningitis. In the Central sub- region, the 
prevalence of serotype 1 decreased by 17.9 % following the 
introduction of PCV13. Serotype 1 has been causing invasive 
disease for a long time and has evolved into distinct lineages 
that have adapted to specific geographical localities [11, 36]. In 
sub- Saharan Africa, serotype 1 encompasses highly virulent 
clones, some of which are capable of causing lethal outbreaks 
of meningitis [10, 37–39].
The high burden of serotype 1 in this sub- region may contribute 
to the lag in decreasing the burden of serotype 1 disease in the 
post- PCV13 period. In Ghana, where a three- dose regimen of 
PCV13 was introduced without a booster, serotype 1 remained 
a common cause of invasive pneumococcal disease up to 3 years 
after the introduction of PCV13, and in that period caused a 
meningitis outbreak among older children and adults in Ghana 
[7, 10, 40]. Experts have previously suggested that a booster 
may be effective in expediting the decline of vaccine serotypes 
Fig. 3. Trends in the presence and absence of antibiotic- resistance genotypes in the context of sub- region and PCV introduction period. (a) 
A column plot showing the proportion of genomes bearing antibiotic- resistance genes among serotypes, which were grouped according 
to whether they were PCV7 serotypes, additional PCV13 serotypes or non- vaccine serotypes. (b) A column plot showing the proportion of 
isolates bearing antibiotic- resistance among isolates from the pre- and post- PCV introduction periods in each sub- region. Note that only 
two isolates from the Eastern sub- region in the pre- PCV introduction period were available.
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in sub- Saharan Africa [41]. In South Africa, a three- dose 
regimen with a booster dose was effective in rapidly decreasing 
the burden of PCV13 serotypes, including serotype 1 [42]. A 
nuanced analysis of the role of boosters is needed based on 
robust epidemiological data or a clinical trial.
The replacement of vaccine serotypes causing invasive diseases 
by non- vaccine serotypes has been reported to various extents in 
several countries following the introduction of PCVs [7, 43–46]. 
The Global Pneumococcal Sequencing consortium has identi-
fied serotype 12F among the top five leading serotypes of the 
post- PCV13 period in at least two different countries [47]. In 
the Central sub- region, the prevalence of non- PCV serotypes, 
including serotype 12F, increased following the introduction 
of PCV13 serotypes. This underscores the need for continued 
surveillance in West Africa, to carefully monitor the role of 
non- vaccine serotypes in the post- PCV13 introduction period.
Antibiotic resistance can contribute to treatment failures and 
negatively impact clinical outcomes [48]. There was no clini-
cally defined resistance to cefotaxime and ceftriaxone, which 
are the primary WHO- recommended antibiotics [49]. Isolates 
bearing the penicillin- resistance pbp genotypes were recovered 
from all sub- regions; this is an important finding because 49 
when neither cefotaxime nor ceftriaxone are available, penicillin 
may be used to treat meningitis.
Championing improved infection management, diagnosis and 
antibiotic stewardship in sub- Saharan Africa may curb the 
emergence and spread of paediatric pneumococcal infections 
that are resistant to the recommended drugs [50–52]. This 
is challenging to implement in a low- resource setting with 
infrastructural constraints; and warrants special attention [53]. 
Vaccines have been proposed as a potential mechanism for 
reducing the burden of antibiotic resistance by lowering the 
risk of infection [54]. This was not reflected in this dataset, as 
a decrease in the prevalence of antibiotic- resistance genes was 
not associated with the post- PCV introduction era, and there 
were no discernible trends regarding the presence of resistance 
genotypes in vaccine and non- vaccine serotypes. While this may 
be reassuring, continued genomic surveillance is required to 
Fig. 4. Antibiotic resistance and resistance genotype patterns in the context of the whole genome phylogeny. A phylogenetic tree with 
branches coloured by serotype and metadata blocks corresponding to sub region, vaccine introduction period, phenotypic antibiotic 
resistance patterns and presence of antibiotic resistance genes for penicillin (PBP, OX), chloramphenicol (cat, C), erythromycin (mef/
ermB, E), co- trimoxazole (folP/ folA, SXT), tetracycline (tetM, TE) and cefotaxime (CTX).
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monitor these trends and to understand the underlying evolu-
tionary mechanisms. We may be missing the contribution of 
novel resistance mechanisms that have not been discovered 
yet and resistance mechanisms that are difficult to predict with 
whole- genome sequencing, such as efflux pump upregulation 
and cell wall permeability changes [55, 56]. Additionally, our 
dataset may be affected by the use of antibiotic prior to hospital 
admission.
Conclusion
Our study underscores the need for continued surveillance for 
monitoring the emergence of non- vaccine serotypes as well as 
residual serotype 1. Genomic surveillance of pneumococcal 
disease and carriage in the African meningitis belt may provide 
an evidence- base to inform future strategies to enhance the 
control of the pneumococcus. Likewise, monitoring of antimi-
crobial resistance using genomic approaches may enhance the 
detection of drug resistant strains and contribute to ensuring 
that patients receive optimal treatment in low- resource settings.
Study limitations
A limitation of this study is that PCVs were introduced in the 
countries which participated in the surveillance at different time 
points and the countries did not use the same PCV formulations 
i.e. PCV10 or PCV13. This made it difficult to get a representa-
tive subset of pre- and post- PCV isolates across all three sub- 
regions. The number of isolates recovered from some countries 
was very low, e.g. there were single isolates from Ivory Coast 
and Democratic Republic of Congo. Grouping the isolates into 
sub- regions made the analysis possible, but this introduced 
potential bias as serotype distributions likely differ between 
and within countries. Furthermore, a limitation of sentinel 
surveillance is that we likely missed a significant proportion of 
pneumococcal meningitis cases that did not attend the sentinel 
sites. This is further compounded by the low culture- recovery 
rates for the pneumococcus across the sub- region. Coordinating 
surveillance in a low- resource setting is extremely challenging. 
This dataset highlights a need to develop laboratory capacity in 
this sub- Saharan Africa.The inability to perform retrospective 
confirmatory MIC testing may have potentially contributed to 
the discrepancies between MICs and genomic predictions.
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